Lanzhou Institute of Biological Products Co., Ltd. (hereinafter referred to as the Company) was founded in 1934 and is one of the oldest biological products research institutes in China. The Company is a legal person enterprise directly under China National Biotech Group Co. Ltd., which is a subsidiary of China National Pharmaceutical Group Co., Ltd. that is under the supervision of the SASAC of the State Council.
The Company is mainly engaged in the production, research, development and operation of preventive products, therapeutic products, diagnostic reagents and other biological products. It is the backbone enterprise of the national biological products industry. The Company is: the only large-scale biological high-tech enterprise in Gansu Province and even in Northwest China; national important research institution in medical microbiology, immunology and molecular biology; state-certified Enterprise Technology Center; national high-tech enterprise; national technological innovation demonstration enterprise; the postdoctoral workstation set up by the State Ministry of Human Resources and has the right to grant master's degree approved by the Academic Degrees Committee of the State Council; the training base for National Institutes for Food and Drug Control; Gansu vaccine engineering technology research center; Gansu macromolecular protein biopharmaceutical engineering research center.
The Company has four specialized research labs and one pilot research lab, which formed distinctive scientific research subjects and research directions. It has established good cooperative relations with world-renowned research institutions in the United States, Japan, Italy, Britain, Hong Kong and other countries and regions.
The Company has achieved fruitful scientific research results. Since 2000, the Company has obtained 3 new Class I drugs, 3 new Class II drugs, 1 new Class III drug, and 31 new Class IV and generic drugs. It also won 1 National Science and Technology Progress First Prize, 5 Second Prize, 2 DuPont Science and Technology Innovation Awards and 18 Provincial and Ministerial Science and Technology Progress Awards.
The main products produced by the Company are: oral Rotavirus Vaccine Live, Group A and Group C Meningococcal Polysaccharide Vaccine, and Type B Haemophilus influenzae Conjugate Vaccine.
The Company's business conception is: All for health, health for all.